Extracorporeal Shockwave Therapy for Diabetic Foot Ulcers (SOLEFUL1)

Extracorporeal Shockwave Therapy for Diabetic Foot Ulcers: A Pilot 3-Arm Randomised Control Trial and Qualitative Study (SOLEFUL).

Summary of the problem:

Diabetes has been described as the fastest growing health crisis of our time. It currently affects more than 4.5million people in the UK. The direct cost to the NHS is already over £1 billion per year. One of the commonest complications of diabetes are foot ulcers. Despite current best treatment, these ulcers can be very difficult to heal, often taking months to heal and some never do. Even after healing ulcers return in up to 60% of people. In England someone undergoes an amputation of part of their foot every 2 hours and every 4 hours someone loses their leg due to diabetic foot ulcers. People are rarely able to be as active as before. This seriously affects their work, finances and quality of life.

Research into improved treatments are a national priority. These treatments need to be safe, effective, tolerable for patients and value for money. Preliminary research has identified shockwave therapy as a promising new treatment in which high-power soundwaves (similar to ultrasound) are delivered to the ulcer. This may make ulcers heal faster. However, the effectiveness of shockwave therapy and the optimum dose is unknown.

The aim of the study:

  1. To carry out a preliminary (pilot) trial comparing sham (not active) shockwaves, low number of shockwaves and high number of shockwaves on diabetic foot ulcer healing
  2. To understand beliefs, concerns, ideas and experience of shockwave therapy amongst patients and clinicians
  3. To investigate the cost effectiveness (value for money) of shockwave therapy

Methods

1. Pilot Trial: Ninety patients with DFU will be randomly assigned to one of three treatment groups:

  1. High dose shockwave treatment
  2. Low dose shockwave treatment
  3. "Sham" shockwave treatment

Each treatment will be delivered in 3x30minute sessions in a 7-day period. Face-to-face follow up appointments will take place 1, 2, 3 and 6 months after treatment to measure ulcer healing and changes in quality-of-life.

Interviews Interviews to explore patient opinion of shockwave therapy, experience in taking part in the trial, reasons patients do not want to take part and clinician attitudes to shockwave therapy

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

There is an urgent need for better treatments for diabetic foot ulcers. Despite current best treatment, diabetic foot ulcers can be very difficult to heal, often taking months to heal and some never do. Even after healing ulcers return in up to 60% of people. In England someone undergoes an amputation of part of their foot every 2 hours and every 4 hours someone loses their leg due to diabetic foot ulcers. People are rarely able to be as active as before. This seriously affects their work, finances and quality of life.

This research is going to look at a new therapy called Extracorporeal Shockwave Therapy. Extracorporeal shockwave therapy (high power soundwaves) is a non-invasive treatment that is delivered directly to the ulcer and may improve healing. However, the effectiveness of shockwave therapy and the optimum dose is unknown. We will investigate if shockwave therapy improves diabetic foot ulcer healing. To do this we will undertake a randomised controlled trial. The trial will randomly allocate people (who are eligible to take part and consent) into one of three groups: sham shockwave therapy, low dose shockwave therapy and high dose shockwave therapy. The patient will not know which group they are in. The researcher collecting wound data will not know which group the patient is in. This is to ensure we and the patient do not influence the results of the study. This is a rigorous way of comparing new treatments to existing ones.

The purpose of the pilot trial is to provide information to be able to repeat this trial again with a larger number of people. This pilot trial will help identify any problems and address any issues before the main trial starts. This minimises the risk of wasting money and people's time.

The aim of this study is to:

  • Carry out a preliminary (pilot) trial comparing sham (not active) shockwave therapy, low number of shockwaves and high number of shockwaves on diabetes foot ulcers
  • To understand beliefs, concerns, ideas and experience of shockwave therapy amongst patients and clinicians

The research has been co-designed by patients and their families with experience of diabetic foot ulcers.

Pilot Trial:

The aim of the pilot trial is to see whether we can recruit enough patients to the study, how many patients remain in the study and reasons why patients leave the trial. It will also test whether we are collecting the information (data) in the right way to answer the research question. This is to make sure that the main trial is successful. Ninety patients who have a diabetic foot ulcer will be randomly assigned to one of the three treatment groups:

  • High dose shockwave therapy
  • Low dose shockwave therapy
  • 'Sham' shockwave therapy

Each treatment will be delivered in a 3x30minute sessions over a 7 day period. All patients will receive usual ulcer care. Face to face follow up appointments will be at 6 weeks, 12 weeks and 24 weeks after study entry to measure ulcer healing, changes in quality of life and health resource use.

Interviews: Patients who are eligible to take part in the trial will be invited to an interview, to explore their reasons for (or for not) taking part, experience undergoing shockwave therapy and thoughts about being in the trial. This is to identify aspects of the trial which patients considered positive/negative so improvements can be made to the main trial. It will also help to improve the main trial and ensure our research is inclusive. Informal interviews, lasting around 30minutes, will be undertaken to explore patient opinion of shockwave therapy, experience of taking part in the trial, reasons patients do not want to take part and clinician attitudes to shockwave therapy. 24 patients and 8 clinicians will be invited to take part.

Study Type

Interventional

Enrollment (Actual)

77

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Hull, United Kingdom, HU3 2JZ
        • Hull University Teaching Hospitals NHS Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 120 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • At least one unhealed diabetic foot ulcer below the level of the medial malleoli that has been present for more than 4 weeks
  • Absolute toe pressure greater than or equal to 50mmHg or an Ankle Pressure Brachial Index (ABPI) equal to or greater than 0.7(24, 25)
  • Capacity to consent to participate in the trial and given written informed consent
  • Willing to be randomised to either sham, low-dose or high-dose ESWT
  • Willing to consent to photography of the index DFU
  • Willing to comply with the follow up schedule

Exclusion Criteria:

  • Interdigital index ulcer. This is because the ESWT delivery paddle does not fit between digits.
  • Currently on or planned treatment for osteomyelitis.
  • Currently taking any therapeutic anticoagulation medications. This includes novel oral anticoagulants, therapeutic doses of heparin and vitamin-K antagonists. This is a contraindication to ESWT.
  • Diagnosis of malignancy in the treatment area or haematological, disseminated or lymphatic malignancy. This is a contraindication to ESWT.
  • All who are pregnant, trying to conceive or breastfeeding. This is a contraindication to ESWT.
  • Active participants in other trials that may conflict with the study outcomes, for example any other wound care trials.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: Sham shockwave therapy
Sham shockwave therapy in standard ulcer care.
ESWT will be given at 0.1mJ/mm2, 5 pulses/second and penetration of 5mm. Each intervention will be delivered in 3x30minute sessions over 7 days.
Active Comparator: Low dose shockwave therapy
100 shocks per cm2 plus standard ulcer care
ESWT will be given at 0.1mJ/mm2, 5 pulses/second and penetration of 5mm. Each intervention will be delivered in 3x30minute sessions over 7 days.
Active Comparator: High dose shockwave therapy
500 shocks per cm2 plus standard ulcer care
ESWT will be given at 0.1mJ/mm2, 5 pulses/second and penetration of 5mm. Each intervention will be delivered in 3x30minute sessions over 7 days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Eligibility ratio and recruitment ratio
Time Frame: 19 months
Number eligible patients/number patients screened / recruited
19 months
Adherence to treatment
Time Frame: 19 months
Number participants who completed the treatment protocol/number participants in the trial.
19 months
Percentage of missing data at each follow up point
Time Frame: 24 weeks
Number of missing data points over number of data points x100
24 weeks
Follow up rates
Time Frame: 6 weeks
No. of participants who attended each follow-up appointments / no. of follow-up appointments .
6 weeks
Follow up rates
Time Frame: 12 weeks
No. of participants who attended each follow-up appointments / no. of follow-up
12 weeks
Follow up rates
Time Frame: 24 weeks
No. of participants who attended each follow-up appointments / no. of follow-up
24 weeks
Patient and clinician acceptability of the trial process and ESWT
Time Frame: 24 weeks
Semi-structured in depth interviews
24 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to DFU healing
Time Frame: 24 weeks
Time taken for ulcer to heal
24 weeks
Proportion of DFUs healed at 6 months
Time Frame: 24 weeks
The number of ulcers healed / total no. of ulcers healed in the trial
24 weeks
Reduction in ulcer size at each study visit
Time Frame: 24 weeks
% reduction in ulcer size
24 weeks
Quality of life questionnaires
Time Frame: 24 weeks
EQ-5L
24 weeks
Quality of life questionnaires
Time Frame: 24 weeks
DFUS
24 weeks
Quality of life questionnaires
Time Frame: 24 weeks
WoundQol
24 weeks
Adverse events
Time Frame: 24 weeks
Instance of amputation, infection, mortality, side effects, re-hospitalisation
24 weeks
Cost differences between ESWT and standard care alone
Time Frame: 24 weeks
Incremental Cost Effectiveness Ratio
24 weeks
Validity, reliability and responsiveness of WoundQol in patients with a DFU
Time Frame: 24 weeks
To test WoundQol-14 reliability of the questionnaire in patients with a diabetic foot ulcer, participants will be asked to complete the questionnaire 3 days before the next follow-up appointment. The WoundQol-14 questionnaire will be repeated at the follow-up appointment. We will also test the validity of using WoundQol-14 over the telephone in patients who struggle to read (for example, due to diabetic retinopathy
24 weeks
Validity, reliability and responsiveness of virtual follow-up for wound healing in research
Time Frame: 24 weeks
To test the feasibility, validity, reliability and responsiveness of virtual follow-up participants will be asked to send a photograph of their ulcer or ulcer site (if healed) 3 days before their follow up appointment to virtually assess the wound. Photographs are anticipated to be taken on the participant's smartphone by either themselves, a family member, friend or the community healthcare professional at dressing changes.
24 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Louise Hitchman, MBBSMRCSMSc, Hull York Medical School

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 13, 2022

Primary Completion (Actual)

October 31, 2023

Study Completion (Estimated)

May 1, 2032

Study Registration Dates

First Submitted

April 22, 2022

First Submitted That Met QC Criteria

May 13, 2022

First Posted (Actual)

May 19, 2022

Study Record Updates

Last Update Posted (Actual)

June 18, 2026

Last Update Submitted That Met QC Criteria

June 16, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data on request.

IPD Sharing Time Frame

Data shared dependent on request, following study completion.

IPD Sharing Access Criteria

Formal written letter to the PI.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe